TCGA-D6-6516-01A-11R-1873-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.640
- INTERFERON_GAMMA_RESPONSE+0.510
- OXIDATIVE_PHOSPHORYLATION+0.330
- MYC_TARGETS_V2+0.290
- MYC_TARGETS_V1+0.280
- G2M_CHECKPOINT+0.260
- PI3K_AKT_MTOR_SIGNALING+0.240
- IL6_JAK_STAT3_SIGNALING+0.210
- P53_PATHWAY+0.210
- DNA_REPAIR+0.200
Top 10 suppressed
- ANGIOGENESIS-0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- MYOGENESIS-0.300
- HYPOXIA-0.170
- COAGULATION-0.160
- TNFA_SIGNALING_VIA_NFKB-0.120
- KRAS_SIGNALING_DN-0.110
- KRAS_SIGNALING_UP-0.100
- GLYCOLYSIS-0.060
- XENOBIOTIC_METABOLISM-0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-7089-01A-11R-2016-07 | — | — | 0.833 |
| 2 | 57AA1143-0FA1-4197-8CBE-517F6B885753 | — | — | 0.816 |
| 3 | E16AD7E1-29DA-4B8F-8B12-A8A6BBAA9174 | — | — | 0.795 |
| 4 | TCGA-XF-AAMQ-01A-11R-A42T-07 | — | — | 0.790 |
| 5 | TCGA-4Z-AA81-01A-11R-A39I-07 | — | — | 0.770 |
| 6 | 88302 | EPN | Supratentorial EPN | 0.761 |
| 7 | TCGA-XF-AAN2-01A-11R-A42T-07 | — | — | 0.759 |
| 8 | TCGA-E7-A7XN-01A-11R-A352-07 | — | — | 0.758 |
| 9 | TCGA-A8-A06X-01A-21R-A00Z-07 | — | B | 0.751 |
| 10 | MNG547 | — | — | 0.751 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.640 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.510 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.330 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.290 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.280 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.210 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.210 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.190 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.180 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.170 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.160 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.150 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.140 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.130 | Idelalisib | — uncovered |